



Resolution n°16-2016-e

Safer, more robust and less expensive antiretroviral first line therapy (ADVANCE trial)

Recalling Resolution n°3-2015-e, in which the UNITAID Board provided its go-ahead for the development by the UNITAID Secretariat of a full draft grant agreement package for the proposed Project “*Safer, more robust and less expensive antiretroviral first line therapy (ADVANCE trial)*” submitted by Wits Reproductive Health & HIV Institute (RHI) a division of Wits Health Consortium (Pty) Ltd; and

Noting the alignment of the Project with the Board-approved Area for Intervention: ‘Improving Adult Antiretroviral Therapy in Low and Middle-income Countries: Providing Support for Evidence-gathering on the Use of New Priority Antiretroviral Regimens for First and Second-line Therapy’;

The Board authorizes, subject to availability of funds, the Executive Director to commit up to USD 12,929,422 for the Project.

Funding is conditional upon signature of the draft grant agreement between UNITAID and Wits RHI.

Lead Organisation: Wits Reproductive Health & HIV Institute (RHI) a division of Wits Health Consortium (Pty) Ltd

Project Duration: 3,5 years, including post-trial access (if required) for 6 months.

A handwritten signature in blue ink, appearing to read "C. Amorim", with a long horizontal line extending to the right.

Celso Amorim
Chair of the UNITAID Executive Board

Date: *November, 1 2016*